Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

@inproceedings{Edwards2016ApremilastAO,
  title={Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)},
  author={Christopher J. Edwards and Francisco J Blanco and Jeffrey J. Crowley and Charles A Birbara and Janusz Jaworski and Jacob A. Aelion and Randall M. Stevens and Adele R Vessey and Xiaojiang Zhan and Paul Bird},
  booktitle={Annals of the rheumatic diseases},
  year={2016}
}
OBJECTIVE To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement, despite prior therapy with conventional disease-modifying antirheumatic drugs and/or biologic agents. METHODS Patients (N=505) were randomised (1:1:1) to placebo, apremilast 20 mg twice daily, or apremilast 30 mg twice daily. Rescue therapy with apremilast was designated at week 16 for placebo patients not achieving 20% improvement in swollen and tender joint counts. At… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Guidelines of care for the management of acne vulgaris.

Journal of the American Academy of Dermatology • 2016

Brodalumab , an antiIL 17 RA monoclonal antibody , in psoriatic arthritis

PJ Mease, MC Genovese, MW Greenwald
N Engl J Med • 2014

phosphodiesterase 4 inhibitor

AO Adebajo, DD Gladman, A Kavanaugh
Ann Rheum Dis 2014;73:1020–6 • 2014

Similar Papers

Loading similar papers…